Burning Rock Biotech
Burning Rock Biotech, a leading player in the biotechnology sector, is headquartered in China and operates extensively across Asia and beyond. Founded in 2014, the company has rapidly established itself as a pioneer in precision oncology, focusing on innovative genomic testing solutions that enhance cancer diagnosis and treatment. The firm’s core offerings include comprehensive genomic profiling and liquid biopsy services, which are distinguished by their accuracy and efficiency. Burning Rock Biotech's commitment to advancing personalised medicine has positioned it as a key contributor to the global fight against cancer, earning recognition for its cutting-edge technology and robust research capabilities. With a strong market presence and notable achievements in regulatory approvals, Burning Rock Biotech continues to drive advancements in the field, making significant strides in improving patient outcomes through tailored therapeutic strategies.
DitchCarbon Score
How does Burning Rock Biotech's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Burning Rock Biotech's score of 36 is higher than 92% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Burning Rock Biotech's reported carbon emissions
As of the latest available data, Burning Rock Biotech, headquartered in China, has not disclosed specific carbon emissions figures. However, the company has set ambitious climate commitments aimed at significantly reducing its greenhouse gas emissions. Burning Rock Biotech has committed to achieving net-zero greenhouse gas emissions across its entire value chain by 2050. In the near term, the company aims to reduce its absolute Scope 1 and Scope 2 emissions by 42% by 2030, using 2022 as the baseline year. Additionally, it plans to transition to 100% renewable electricity sourcing by 2030, up from 0% in 2022. For Scope 3 emissions, which encompass indirect emissions from the company's value chain, Burning Rock Biotech targets a 25% reduction by 2030. Looking further ahead, the company has set a long-term goal to reduce both its Scope 1 and Scope 2 emissions by 90% and its Scope 3 emissions by 90% by 2050, again using 2022 as the baseline. These commitments align with industry standards for climate action and reflect a proactive approach to addressing climate change.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Burning Rock Biotech is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
